494 SECTION 2 Pathology of Organ Systems
impaired, lesions can progress to an irreversible stage in which
restoration of alveolar structure is no longer possible. In diseases,
such as extrinsic allergic alveolitis, the constant release of pro-
teolytic enzymes and free radicals by phagocytic cells perpetu-
ates alveolar damage in a vicious circle. In other cases, such as in
paraquat toxicity, the magnitude of alveolar injury can be so severe
that type II pneumonocytes, basement membranes, and alveolar
interstitium are so disrupted that the capacity for alveolar repair
is lost. Fibronectins and transforming growth factors (TGFs)
released from macrophages and other mononuclear cells at the
site of chronic in!ammation regulate the recruitment, attachment,
and proliferation of $broblasts. In turn, these cells synthesize and
release considerable amounts of ECM (collagen, elastic $bers, or
proteoglycans), eventually leading to $brosis and total obliteration
of normal alveolar architecture. In summary, in diseases in which
there is chronic and irreversible alveolar damage, lesions invariably
progress to a stage of terminal alveolar and interstitial $brosis.
Alveolar Filling Disorders
Alveolar $lling disorders are a heterogeneous group of lung diseases
characterized by accumulation of various chemical compounds in
the alveolar lumens. "e most common are alveolar proteinosis in
which the alveoli are $lled with $nely granular eosinophilic mate -
rial; alveolar microlithiasis in which the alveoli contain numerous
concentric calci$ed “microliths” or “calcospherites.” A similar but
distinct concretion is known as corpora amylacea, which is an accu-
mulation of cholesterol (cholesterol pneumonitis) or lipids (endog-
enous lipid pneumonia; see the section on Other Pneumonias of
Cats). "ere is often little host response, and in many cases, it is
only an incidental $nding. Some of the alveolar $lling disorders
originate from inherited metabolic defects in which alveolar cells
(epithelial or macrophages) cannot properly metabolize or remove
lipids or proteins while others result from an excessive synthesis of
these substances in the lung.
Classification of Pneumonias
Few subjects in veterinary pathology have caused so much debate
as the classi$cation of pneumonias. Historically, pneumonias in
animals have been classi$ed or named based on the following:
1. Presumed cause, with names such as viral pneumonia,
Pasteurella pneumonia, distemper pneumonia, vermin-
ous pneumonia, chemical pneumonia, and hypersensitivity
pneumonitis
2. Type of exudation, with names such as suppurative pneumo-
nia, $brinous pneumonia, and pyogranulomatous pneumonia
3. Morphologic features, with names such as gangrenous pneu-
monia, proliferative pneumonia, and embolic pneumonia
4. Distribution of lesions, with names such as focal pneumo-
nia, cranioventral pneumonia, di#use pneumonia, and lobar
pneumonia
5. Epidemiologic attributes, with names such as enzootic
pneumonia, contagious bovine pleuropneumonia, and “ship-
ping fever”
6. Geographic regions, with names such as Montana progres-
sive pneumonia
7. Miscellaneous attributes, with names such as atypical pneu-
monia, cu%ng pneumonia, progressive pneumonia, aspira -
tion pneumonia, pneumonitis, farmer’s lung, and extrinsic
allergic alveolitis
Until a universal and systematic nomenclature for animal pneu-
monias are established, veterinarians should be acquainted with
this heterogeneous list of names and should be well aware that
one disease may be known by di#erent names. In pigs, for instance,
Movement of plasma proteins into the pulmonary intersti-
tium and alveolar lumen is a common but poorly understood
phenomenon in pulmonary in!ammation. Leakage of $brinogen
and plasma proteins into the alveolar space occurs when there
is structural damage to the blood-air barrier. "is leakage is also
promoted by some types of cytokines that enhance procoagulant
activity, whereas others reduce $brinolytic activity. Excessive exuda -
tion of $brin into the alveoli is particularly common in ruminants
and pigs. "e $brinolytic system plays a major role in the resolu-
tion of pulmonary in!ammatory diseases. In some cases, exces -
sive plasma proteins leaked into alveoli mix with necrotic type I
pneumonocytes and pulmonary surfactant, forming microscopic
eosinophilic bands (membranes) along the lining of alveolar septa.
"ese membranes, known as hyaline membranes, are found in spe-
ci$c types of pulmonary diseases, particularly in ARDS, and in
cattle with acute interstitial pneumonias such as bovine pulmonary
edema and emphysema and extrinsic allergic alveolitis (see Figs.
9-37 and 9-45).
In the last few years, nitric oxide has been identi$ed as a major
regulatory molecule of in!ammation in a variety of tissues, includ -
ing the lung. Produced locally by macrophages, pulmonary endo-
thelium, and pneumonocytes, nitric oxide regulates the vascular and
bronchial tone, modulates the production of cytokines, controls the
recruitment and tra%cking of neutrophils in the lung, and switches
on/o# genes involved in in!ammation and immunity. Experimental
work has also shown that pulmonary surfactant upregulates the
production of nitric oxide in the lung, supporting the current view
that pneumonocytes are also pivotal in amplifying and downregu-
lating the in!ammatory and immune responses in the lung (see
Web Table 9-1).
As the in!ammatory process becomes chronic, the types of
cells making up cellular in$ltrates in the lung change from mainly
neutrophils to largely mononuclear cells. "is shift in cellular com -
position is accompanied by an increase in speci$c cytokines, such
as IL-4, interferon-γ (IFN-γ), and interferon-inducible protein
(IP-10), which are chemotactic for lymphocytes and macrophages.
Under appropriate conditions, these cytokines activate T lym-
phocytes, regulate granulomatous in!ammation, and induce the
formation of multinucleated giant cells such as in mycobacterial
infections.
In!ammatory mediators locally released from in!amed lungs
also have a biologic e#ect in other tissue. For example, pulmo -
nary hypertension and right-sided heart failure (cor pulmonale)
often follows chronic alveolar in!ammation, not only as a result
of increased pulmonary blood pressure but also from the e#ect of
in!ammatory mediators on the contractibility of smooth muscle
of the pulmonary and systemic vasculature. Cytokines, particularly
TNF-α, which are released during in!ammation are associated,
both as cause and e#ect, with the systemic in!ammatory response
syndrome (SIRS), sepsis, severe sepsis with multiple organ dysfunc-
tion, and septic shock (cardiopulmonary collapse).
As it occurs in any other sentinel system where many biologic
promoters and inhibitors are involved (coagulation, the comple-
ment and immune systems), the in!ammatory cascade could go
into an “out-of-control” state, causing severe damage to the lungs.
Acute lung injury (ALI), extrinsic allergic alveolitis, ARDS, pulmo-
nary $brosis, and asthma are archetypical diseases that ensue from
an uncontrolled production and release of cytokines.
As long as acute alveolar injury is transient and there is no
interference with the normal host response, the entire process of
injury, degeneration, necrosis, in!ammation, and repair can occur
in less than 1 week. On the other hand, when acute alveolar injury
becomes persistent or when the capacity of the host for repair is